Trials / Completed
CompletedNCT00170755
A Long-Term Safety, Tolerability and Efficacy Study of Darifenacin in Adult Patients With Overactive Bladder
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 718 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
This study will evaluate the safety, tolerability and efficacy of darifenacin, in the long-term treatment of adult patients with overactive bladder.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Darifenacin | Darifenacin 7,5 mg tablets, Darifenacin 15 mg tablets administered once daily |
Timeline
- Start date
- 2002-04-01
- Completion
- 2005-01-01
- First posted
- 2005-09-15
- Last updated
- 2008-01-17
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00170755. Inclusion in this directory is not an endorsement.